# EDGAR Filing Document

**Accession Number:** 0001815974
**File Stem:** 0001493152-25-015078
**Filing Date:** 2025-9
**Character Count:** 5643
**Document Hash:** 66c8e21163f51b8d893041e35d372419
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-015078.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001493152-25-015078

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**EFFECTIVENESS DATE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anebulo Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001815974
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851170950
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287311
- **FILM NUMBER:** 251345685

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ANEBULO PHARMACEUTICALS, INC.
- **STREET 2:** 1017 RANCH ROAD 620 SOUTH, SUITE 107
- **CITY:** LAKEWAY
- **STATE:** TX
- **ZIP:** 78734
- **BUSINESS PHONE:** 737 203 5270

**MAIL ADDRESS:**
- **STREET 1:** C/O ANEBULO PHARMACEUTICALS, INC.
- **STREET 2:** 1017 RANCH ROAD 620 SOUTH, SUITE 107
- **CITY:** LAKEWAY
- **STATE:** TX
- **ZIP:** 78734

**As filed with the Securities and Exchange Commission on September 26, 2025**

**Registration No. 333-264432**

**Registration No. 333-287311**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264432**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-287311** 

 ****

**UNDER**

**THE SECURITIES ACT OF 1933**

**ANEBULO PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **85-1170950** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification Number) |
| **1017 Ranch Road 620 South, Suite 107**<br> **Lakeway, Texas** | **78734** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Anebulo Pharmaceuticals, Inc. 2020 Stock Incentive Plan**

(Full title of the plan)

**Richard Anthony Cunningham**

**Chief Executive Officer**

**Anebulo Pharmaceuticals, Inc.**

**1017 Ranch Road 620 South, Suite 107**

**Lakeway, Texas 78734**

(Name, address of agent for service)

**(512) 598-0931**

(Telephone number, including area code, of agent for service)

***Copies to:***

**Leslie Marlow, Esq.**

**Melissa Murawsky, Esq.**

**Blank Rome LLP**

**1271 Avenue of the Americas**

**New York, New York 10020**

**(212) 885-5000**

(Name, address and telephone number)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**DEREGISTRATION OF SECURITIES**

These Post-Effective Amendments (these "**Post-Effective Amendments**") relate to the following Registration Statements on Form S-8 (collectively, the "**Registration Statements**"), filed with the Securities and Exchange Commission (the "**SEC**") by Anebulo Pharmaceuticals, Inc., a Delaware corporation (the "**Company**"):

● Registration Statement No. 333-264432, registering 2,667,500 shares of the Company's common stock, par value $0.001 per share (the "**Common Stock** "), issuable pursuant to the Company's 2020 Stock Incentive Plan (the "**2020 Plan** "), which was filed with the SEC on April 22, 2022; and

● Registration Statement No. 333-287311, registering 2,500,000 shares of Common Stock, issuable pursuant to the Company's 2020 Plan, which was filed with the SEC on May 15, 2025.

The Company is filing these Post-Effective Amendments to the Registration Statements to withdraw and remove from registration the shares of Common Stock remaining unsold pursuant to the Registration Statements.

In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any shares of Common Stock that had been registered for issuance but remain unsold at the termination of the offering, the Company hereby removes from registration any and all shares of the Company's Common Stock registered but unsold under the Registration Statemenst as of the date hereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lakeway, State of Texas, on September 26, 2025.

---

| | |
|:---|:---|
| **ANEBULO PHARMACEUTICALS, INC.** | **ANEBULO PHARMACEUTICALS, INC.** |
| By: | */s/ Richard Anthony Cunningham* |
| Name: | Richard Anthony Cunningham |
| Title: | Chief Executive Officer |

---

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statements.